Your browser doesn't support javascript.
loading
Prevention and treatment of SHIVAD8 infection in rhesus macaques by a potent d-peptide HIV entry inhibitor.
Nishimura, Yoshiaki; Francis, J Nicholas; Donau, Olivia K; Jesteadt, Eric; Sadjadpour, Reza; Smith, Amanda R; Seaman, Michael S; Welch, Brett D; Martin, Malcolm A; Kay, Michael S.
Afiliação
  • Nishimura Y; Laboratory of Molecular Microbiology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892.
  • Francis JN; Department of Biochemistry, University of Utah School of Medicine, Salt Lake City, UT 84112.
  • Donau OK; Navigen, Inc., Salt Lake City, UT 84108.
  • Jesteadt E; Laboratory of Molecular Microbiology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892.
  • Sadjadpour R; Laboratory of Molecular Microbiology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892.
  • Smith AR; Laboratory of Molecular Microbiology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892.
  • Seaman MS; Department of Biochemistry, University of Utah School of Medicine, Salt Lake City, UT 84112.
  • Welch BD; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA 02215.
  • Martin MA; Navigen, Inc., Salt Lake City, UT 84108.
  • Kay MS; Laboratory of Molecular Microbiology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892; malm@nih.gov kay@biochem.utah.edu.
Proc Natl Acad Sci U S A ; 117(36): 22436-22442, 2020 09 08.
Article em En | MEDLINE | ID: mdl-32820072
ABSTRACT
Cholesterol-PIE12-trimer (CPT31) is a potent d-peptide HIV entry inhibitor that targets the highly conserved gp41 N-peptide pocket region. CPT31 exhibited strong inhibitory breadth against diverse panels of primary virus isolates. In a simian-HIV chimeric virus AD8 (SHIVAD8) macaque model, CPT31 prevented infection from a single high-dose rectal challenge. In chronically infected animals, CPT31 monotherapy rapidly reduced viral load by ∼2 logs before rebound occurred due to the emergence of drug resistance. In chronically infected animals with viremia initially controlled by combination antiretroviral therapy (cART), CPT31 monotherapy prevented viral rebound after discontinuation of cART. These data establish CPT31 as a promising candidate for HIV prevention and treatment.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Infecções por HIV / HIV / Vírus da Imunodeficiência Símia / Fármacos Anti-HIV / Internalização do Vírus Limite: Animals Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Infecções por HIV / HIV / Vírus da Imunodeficiência Símia / Fármacos Anti-HIV / Internalização do Vírus Limite: Animals Idioma: En Ano de publicação: 2020 Tipo de documento: Article